Long term cultures of human monocytes in vitro impact of GM-CSF on survival and differentiation

Eischen, Alice; Vincent, Florence; Bergerat, Jean‐Pierre; Louis, Bruno; Faradji, A.; Bohbot, Alain; Oberling, F.

doi:10.1016/0022-1759(91)90046-i

Cited by 49 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 2 depicts the scheme of MAC adoptive immunotherapy. The recovery of MAC from blood MO seeded initially can be increased by the addition of granulocytemacrophage colony-stimulating factor (GM-CSF) [39]. Serumfree conditions have also been developed [40][41][42].…”

Section: Adoptive Immunotherapy With Human Mac Cellsmentioning

confidence: 99%

Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives

Andreesen

Hennemann

Krause

1998

Journal of Leukocyte Biology

144

110

View full text Add to dashboard Cite

Section: Adoptive Immunotherapy With Human Mac Cellsmentioning

confidence: 99%

Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives

Andreesen

Hennemann

Krause

1998

Journal of Leukocyte Biology

144

110

View full text Add to dashboard Cite

“…28 Therefore, the infection of cytokine-stimulated cytotoxic effector cells with a viral vector encoding a tumor-specific mAb is a realistic approach for the generation of tumor Ag-specific cytotoxic cells for cancer therapy. This approach combines the high specificity of TAA mAb with the cytotoxic activity and the tumor accumulation (homing of these effector cells).…”

Section: Discussionmentioning

confidence: 99%

“…In vitro differentiation of human monocytes in mature and functionally competent macrophages was achieved by 7 days of culture in the presence of 50 U/mL of recombinant human GM-CSF as described elsewhere. 28 The phenotype of the infected cells was verified by cytofluorimetry using a mouse anti-human CD14 mAb.…”

Section: Establishment and Maintenance Of Cytotoxic Cellsmentioning

confidence: 99%

Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody

et al. 2000

View full text Add to dashboard Cite

Cytotoxicity is an important function of the immune system that results in the destruction of cellular targets by humoral and/or cellular mechanisms. We wanted to assess the possibility of targeting the lytic function of immune cells toward cancer cells, which express the gene coding for a known tumor antigen (Ag) (GA733-2/epithelial cell adhesion molecule), using a viral vector encoding a monoclonal antibody (mAb) specific for said tumor Ag (CO17-1A). To this end, we have constructed recombinant vaccinia viruses expressing the sequences corresponding to mAb CO17-1A, which recognizes a specific Ag (GA733-2) that is present on the surface of most gastrointestinal carcinomas. The recombinant vectors encoding either a secreted or membrane-anchored form of CO17-1A mAb were used to infect effector cells, which were subsequently assessed for their cytotoxic activity. The recombinant viruses were able to infect both granulocyte-macrophage colony-stimulating factor-activated human macrophages and Ag-stimulated murine cytotoxic T lymphocytes. Infected granulocyte-macrophage colony-stimulating factor-activated macrophages were found to be able to kill GA733-2-expressing tumor cells. Likewise, infected cytotoxic T lymphocytes, although conserving their original alloreactivity, gained the capability of killing GA733-2-expressing cancer cells. Cancer Gene Therapy (2000) 7, 615-623

show abstract

“…37,38 Microglial cultures were prepared according to standard methods 39,40 from fresh human fetal brain tissue obtained from the Human Fetal Tissue Bank (Albert Einstein College of Medicine, Bronx, NY, USA). Briefly, human fetal CNS cell cultures were prepared from second trimester abortuses by enzymatic and mechanical dissociation.…”

Section: Cell Linesmentioning

confidence: 99%

Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5

Cordelier

Kulkowsky

et al. 2004

Gene Ther

View full text Add to dashboard Cite

The CCR5 chemokine receptor is important for most clinical strains of HIV to establish infection. Individuals with naturally occurring polymorphisms in the CCR5 gene who have reduced or absent CCR5 are apparently otherwise healthy, but are resistant to HIV infection. With the goal of reducing CCR5 and protecting CCR5+ cells from R5-tropic HIV, we used Tag-deleted SV40-derived vectors to deliver several anti-CCR5 transgenes: 2C7, a single-chain Fv (SFv) antibody; VCKA1, a hammerhead ribozyme; and two natural CCR5 ligands, MIP-1a and MIP-1b, modified to direct these chemokines, and hence their receptor to the endoplasmic reticulum. These transgenes were delivered using recombinant, Tag-deleted SV40-derived vectors to human CCR5+ cell lines and primary cells: monocyte-derived macrophages and brain microglia. All transgenes except MIP-1a decreased CCR5, as assayed by immunostaining, Northern blotting, and cytofluorimetry (FACS). Individually, all transgenes except MIP-1a protected from low challenge doses of HIV. At higher dose HIV challenges, protection provided by all transgenes diminished, the SFv and the ribozyme being most potent. Vectors carrying these two transgenes were used sequentially to deliver combination anti-CCR5 genetic therapy. This approach gave approximately additive reduction in CCR5, as measured by FACS and protected from higher dose HIV challenges. Reducing cell membrane CCR5 using anti-CCR5 transgenes, alone or in combinations, may therefore provide a degree of protection from R5-tropic strains of HIV.

show abstract

Long term cultures of human monocytes in vitro impact of GM-CSF on survival and differentiation

Cited by 49 publications

References 34 publications

Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives

Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives

Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody

Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5

Contact Info

Product

Resources

About